CYP3A4 Experiment - MDZ probe CSV JSON

In Vivo Interaction Study

CYP3A4 Experiment - MDZ probe

Increased systemic exposure was detected.

midazolam 708298

  • CYP3A4 4306811

Results

Control is pre-goldenseal administration 
Test is post-goldenseal administration
Data from Table 1/Table 2

Compound measured Measurement Value Study sequence Additional information N replicates

Experimental Conditions

Multiple dosing

Population

Females
Males

Nonsmokers

16

8 women. 

Normal diet, and were not users of botanical dietary supplements; nor were they taking any prescription medications. All female subjects had a negative pregnancy test at baseline, and

Pharmacokinetic (PK) Sampling Information

0, 0.25, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, and 6 h

Drug or Natural Product Administration

Object Administration — midazolam

Oral

Unspecified

8 mg with 240 mL of water

14 days administered 24h before the start of each supplementation/medication phase (baseline) and again on the last day of each phase.

Precipitant Administration — goldenseal root extract

Oral

Capsule

3969 mg

three times daily

14 days

Natural Product Characteristics

Nautre’s Resource Products

OI10184

not specified

standardized to contain 24.1 mg isoquinoline alkaloids per capsule